Edmund Harrigan
Known title: DirectorCIK: 0001177917
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
Transaction History
| INCY | ▲ Buy | Grant | 206 | $25K | 9/30/2026 | View on chart |
| INCY | ▲ Buy | Grant | 255 | $29K | 6/30/2026 | View on chart |
| INCY | ▲ Buy | Grant | 1,642 | $0 | 6/8/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 8,107 | — | 5/29/2026 | View on chart |
| INCY | ▲ Buy | Grant | 269 | $25K | 3/31/2026 | View on chart |
| INCY | ▲ Buy | Grant | 245 | $24K | 12/31/2025 | View on chart |
| INCY | ▲ Buy | Grant | 289 | $25K | 9/30/2025 | View on chart |
| INCY | ▲ Buy | Grant | 367 | $25K | 6/30/2025 | View on chart |
| INCY | ▲ Buy | Grant | 2,518 | $0 | 6/10/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,387 | — | 5/29/2025 | View on chart |
| INCY | ▲ Buy | Grant | 363 | $22K | 3/31/2025 | View on chart |
| INCY | ▲ Buy | Grant | 339 | $23K | 12/31/2024 | View on chart |
| INCY | ▲ Buy | Grant | 378 | $25K | 9/30/2024 | View on chart |
| INCY | ▲ Buy | Grant | 409 | $25K | 6/28/2024 | View on chart |
| INCY | ▲ Buy | Grant | 2,830 | $0 | 6/12/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,652 | — | 5/29/2024 | View on chart |
| INCY | ▲ Buy | Grant | 413 | $24K | 3/28/2024 | View on chart |
| INCY | ▲ Buy | Grant | 423 | $27K | 12/29/2023 | View on chart |
| INCY | ▲ Buy | Grant | 389 | $22K | 9/29/2023 | View on chart |
| INCY | ▲ Buy | Grant | 390 | $24K | 6/30/2023 | View on chart |
| INCY | ▲ Buy | Grant | 2,505 | $0 | 6/14/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 8,552 | — | 6/1/2023 | View on chart |
| INCY | ▲ Buy | Grant | 326 | $24K | 3/31/2023 | View on chart |
| INCY | ▲ Buy | Grant | 302 | $24K | 12/30/2022 | View on chart |
| INCY | ▲ Buy | Grant | 165 | $11K | 10/19/2022 | View on chart |
| INCY | ▲ Buy | Grant | 250 | $17K | 9/30/2022 | View on chart |
| INCY | ▲ Buy | Grant | 236 | $18K | 6/30/2022 | View on chart |
| INCY | ▲ Buy | Grant | 2,144 | $0 | 6/15/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,391 | — | 6/7/2022 | View on chart |
| INCY | ▲ Buy | Grant | 240 | $19K | 3/31/2022 | View on chart |
| INCY | ▲ Buy | Grant | 253 | $19K | 12/31/2021 | View on chart |
| INCY | ▲ Buy | Grant | 237 | $16K | 9/30/2021 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 3,059 | — | 6/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Incyte receives mixed analyst updates with price target changes
Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.
Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.